A Study to Evaluate the Safety and Immunogenicity of ChAdOx1-VZV in Healthy Adults Aged 50-65 Years
NCT ID: NCT05991427
Last Updated: 2024-12-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
65 participants
INTERVENTIONAL
2023-11-07
2024-11-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental vaccine group, low dose, Intramuscular injection(IM)
2 doses of ChAdOX1-VZV vaccine (1 × 10\^10 vp) on Day 0 and Month 4
Recombinant Zoster Vaccine (Adenovirus Vector) (ChAdOx1-VZV)
2 doses of ChAdOX1-VZV vaccine on Day 0 and Month 4
Control vaccine group, low dose, IM
2 doses of Shingrix vaccine (0.5ml) on Day 0 and Month 4
Zoster Vaccine Recombinant, Adjuvanted (Shingrix)
2 doses of Shingrix vaccine on Day 0 and Month 4
Experimental vaccine group, high dose, IM
2 doses of ChAdOX1-VZV vaccine (5 × 10\^10 vp) on Day 0 and Month 4
ChAdOx1-VZV
2 doses of ChAdOX1-VZV vaccine on Day 0 and Month 4
Control vaccine group, high dose, IM
2 doses of Shingrix vaccine (0.5ml) on Day 0 and Month 4
Shingrix
2 doses of Shingrix vaccine on Day 0 and Month 4
Experimental vaccine group, Aerosol, Inhalation(IH)
2 doses of ChAdOX1-VZV vaccine (2 × 10\^10 vp) on Day 0 and Month 4
IH ChAdOx1-VZV
2 doses of ChAdOX1-VZV vaccine on Day 0 and Month 4
Saline group, Aerosol, IH
2 doses of saline (0.2ml) on Day 0 and Month 4
IH saline
2 doses of saline on Day 0 and Month 4
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Recombinant Zoster Vaccine (Adenovirus Vector) (ChAdOx1-VZV)
2 doses of ChAdOX1-VZV vaccine on Day 0 and Month 4
Zoster Vaccine Recombinant, Adjuvanted (Shingrix)
2 doses of Shingrix vaccine on Day 0 and Month 4
ChAdOx1-VZV
2 doses of ChAdOX1-VZV vaccine on Day 0 and Month 4
Shingrix
2 doses of Shingrix vaccine on Day 0 and Month 4
IH ChAdOx1-VZV
2 doses of ChAdOX1-VZV vaccine on Day 0 and Month 4
IH saline
2 doses of saline on Day 0 and Month 4
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male and female volunteers aged 50 to 65 years at time of informed consent.
* Healthy or in stable health participants with pre-existing, stable, well-controlled disease, defined as mild disease or medical condition not requiring medical therapy or not requiring a change in medical therapy due to worsening of disease during the 6 months before enrollment may be enrolled at the discretion of the investigator.
* Female participants of childbearing potential must have a negative urine pregnancy test at screening and before each dose of investigational vaccine and have been using an adequate form of contraception 30 days prior to first dose of investigational vaccine and agree to use adequate contraception for the entire duration of their participation in the study.
* Male participants must agree to use adequate contraception from the first dose of investigational vaccine until at least 30 days after the last dose of investigational vaccine.
Exclusion Criteria
* History of severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine.
* History of herpes zoster (HZ) (Shingles) in the past 5 years.
* Previous vaccination against HZ.
* History of or present substance abuse as judged by the investigator.
* Immunosuppression resulting from hematopoietic stem cell transplantation, acquired immunodeficiency syndrome (AIDS) or symptomatic (human immunodeficiency virus) HIV infection.
* Chronic administration of immunosuppressants (at least 10 mg per day of prednisone equivalent for glucocorticoids) or other immune-modifying drugs within 6 months prior to the first dose of investigational vaccine.
* Has received any blood products or immunoglobulin within 90 days prior to study injection, or is likely to require infusion of blood products during the study period.
* Is undergoing chemotherapy or expected to receive chemotherapy during the study period; has a diagnosis of or receiving treatment for cancer within the last 5 years.
* History of clinically significant thrombocytopenia or other clotting disorders.
* Serious cardiovascular disease (pulmonary heart disease, pulmonary edema, hypertension that cannot be controlled by medication (systolic blood pressure \> 160 mmHg and/or diastolic blood pressure \> 100 mmHg)), serious liver and kidney disease, and diabetes mellitus with complications.
* History of allergic skin diseases.
* Use of any investigational or non-registered product (drug or vaccine) within 30 days before the first dose of investigational vaccine/product, or planned use during the study period.
* Receipt of any other immunizations within one month before the first dose of investigational vaccine (2 weeks in the case of inactivated influenza vaccines or other non-replicating immunization products \[e.g., tetanus and reduced dose diphtheria toxoid (dT) vaccine, pneumococcal vaccine, hepatitis A vaccine, hepatitis B vaccine\]), or scheduled within 30 days after last dose of investigational vaccine.
* Received a vaccine with adenovirus vector within 6 months prior to the first dose of investigational vaccine.
* Investigator site staff directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.
* Volunteers with or have history of lung function abnormalities such as asthma, chronic obstructive pulmonary disease, and pulmonary fibrosis.
* Current smokers.
* History or current evidence of any condition, therapy, or laboratory abnormal values that are clinically significant which might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participants to participate, in the opinion of the treating investigator.
50 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CanSino Biologics Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Scot Halperin, MD
Role: PRINCIPAL_INVESTIGATOR
Canadian Center for Vaccinology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Canadian Center for Vaccinology
Halifax, , Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CTP-CVE-001
Identifier Type: -
Identifier Source: org_study_id